The study, called Com-COV3, will test different vaccine schedules in 12- to 16-year-olds, looking at the immune responses and milder side-effects. "The concern here is about the risks of myocarditis, particularly with the second dose with Pfizer vaccine in young men," the trial's lead researcher, Matthew Snape of the Oxford Vaccine Group, told reporters. The trial will give all participants a first dose of the Pfizer-BioNTech vaccine. That will be followed eight weeks later by either a second full dose or a half dose of the Pfizer shot, a full dose of Novavax's vaccine or a half dose of Moderna's shot. Snape is running another arm of the trial in adults, giving mixed vaccine schedules both four and 12 weeks apart, and comparing the responses.

Source: Mint September 16, 2021 22:52 UTC